Chembio’s DPP Zika/Dengue/Chikungunya multiplex test allows simultaneous and discrete detection of antibodies for both active (IgM) and prior exposure (IgG) to the Zika, dengue, and chikungunya viruses, which is important for both treatment and surveillance. The test is performed using a small (10µL) drop of fingertip blood and provides quantitative results in approximately 15 minutes when used with the company’s handheld DPP Micro Reader.

“We are pleased to receive the CE mark for our multiplex test designed to detect Zika, dengue, and chikungunya viruses and look forward to commercializing this test in the eligible European and Caribbean nations,” stated John Sperzel, Chembio’s Chief Executive Officer. “Co-circulation of these three arboviruses, which can produce similar patient symptoms, hampers clinical differential diagnoses. We believe our multiplex test can be an important tool in combating these serious and sometimes deadly diseases.”